Review Article

Zohair Jamil Gazzaz*

Diabetes and COVID-19

1 Introduction

The COVID-19 pandemic has profoundly influenced the economic outlook and psychosocial well-being worldwide.
A retrospective Chinese study suggested that COVID-19 patients with diabetes had a higher incidence of hypertension (56.9%), cardiovascular disease (CVD) (20.9%), and cerebrovascular disease (7.8%) compared to non-DM patients (28.8, 11.1, and 1.3%, respectively) [15]. A population-based cohort study from England reported a greater possibility of death from COVID-19 in patients with diabetes (either type 1 or type 2 DM) with HbA1c > 10% relative to those with HbA1c < 6.5% [16].

2 COVID-19 and comorbidities

The dynamics of pathophysiology are still being recognized around the world. Elderly COVID-19 patients with comorbidities have severe and fatal issues [17,18]. A nationwide analysis conducted on 1,590 laboratory-confirmed patients in China had a mean age of 49 years, with 399 (25.1%) patients had at least one comorbid disease. Hypertension was the most predominant (16.9%), followed by DM (8.2%). A small number of patients, 130 (8.2%), had two or more comorbidities. The findings suggest that COVID-19 patients with some comorbidity had worse clinical results compared to those without an associated condition, and more comorbidities were also associated with poorer clinical outcomes [19]. In another case series that had 5,700 confirmed cases of COVID-19, the commonly prevalent comorbidities were hypertension (3,026; 56.6%), obesity (1,737; 41.7%), and DM (1,808; 33.8%), who were hospitalized in the New York City region [20].

One Chinese meta-analysis involved 1,527 patients and considered hypertension to be the most frequent cardiovascular comorbidity in COVID-19 (17.7%), cerebrovascular disease (16.4%), and DM (9.7%). Furthermore, diabetic or hypertensive patients had a two-fold increased risk of developing serious complications or requiring ICU admissions. In contrast, cardio-cerebrovascular illness patients had a three-fold rise [13].

3 How COVID-19 impacts DM patients

DM is a metabolic disease illustrated by chronic high circulating blood glucose concentration in the body [21]. The worldwide prevalence of DM has increased drastically, with 463 million people suffering from the disease globally in 2019, with 95% of type 2 DM [21]. Currently, many patients who have diabetes remain undiagnosed with the disease. The therapeutic intervention has reduced disease complications, making it necessary to detect diabetes early on in its course. DM occurs throughout the world, but it is found explicitly in the more developed countries, where the majority of the patients are in the age group between 45 and 64 years. A relationship has been clinically recognized between diabetic individuals and infections [22]. A virus that causes pneumonia, particularly influenza, is prevalent and presents a much more profound threat in older patients with type 2 DM [23,24].

There is a higher chance of poor prognosis and death for COVID-19 patients with diabetes. With the high global incidence of diabetes, these individuals constitute a significant portion of the population susceptible to COVID-19. Several factors are linked with a higher risk of mortality from COVID-19, including male gender, increased age, hypertension, DM, obesity, CVDs, chronic obstructive pulmonary disease, and cancer [25].

Reports from countries such as China [13,17,19], Italy [26], and the City of New York [20] have shown that older age and chronic diseases such as DM, hypertension, and extreme obesity are now considered to augment morbidity and death in COVID-19 patients. It is indistinct whether DM leads individually to elevated risk, but blood glucose and DM predict morbidity and death in SARS patients [27].

An American study reported that in 1,122 patients admitted in hospital for COVID-19, the rate of mortality during hospital stays of those suffering from diabetes or hyperglycemia was four-fold higher (28.8%) than that of patients with normal glucose level (6.2%) [28]. A reduced chance of complications and the all-cause death rate were also linked with good glycemic regulation [29]. Al Hayek et al. investigated the factors that may raise the risk of hospital admission of COVID-19 patients with diabetes. They reported patients’ hospitalization was independently associated with a high HbA1c level in Saudi patients [30].

A Chinese meta-analysis reported that high HbA1c is a predictor of the in-hospital mortality of COVID-19 patients [31]. Individuals with elevated HbA1c are at high risk for COVID-19. They should comply with the doctor’s recommendation and precisely track and regulate glucose metabolism regularly [31]. It has been proposed that diabetes could potentiate the severity of SARS-CoV-2 infection via diverse routes that eventually contribute to advanced glycation end products, glucose toxicity, endothelitis, vital organ injury, and fatality [32].
It is reported that ACE2 receptors mediate the SARS-CoV-2 effects in the host cells. ACE2 receptors are present in the respiratory system, type 1 and 2 alveolar cells of the lungs, hearts, kidney tubules, enterocytes, and pancreas. Studies conducted on rodent models of DM have demonstrated that there has been an augmented manifestation of ACE2 receptors in the lungs, heart, kidney, and pancreas [33,34]. Furthermore, a randomized study found that increased lung ACE2 expression was linked with DM [35]. Furthermore, DM patients have higher circulating Furin levels, a cellular protease that cleaves S1 and S2 domains of spike protein, facilitating the access of SARS-CoV-2 [36]. These studies support that DM patients present a higher COVID-19 risk, and diabetic individuals infected with the disease have impaired virus clearance [37]. ACE2 helps in the catalytic conversion of angiotensin 2 to angiotensin 1–7 or angiotensin 1–9. This conversion is essential as it has a protective effect on the lungs against ARDS [38]. This protective action is because of the antioxidant and anti-inflammatory action of angiotensin 1–7 and angiotensin 1–9. Unfortunately, once the SARS-CoV-2 virus binds with ACE2, it is degraded, preventing any protective action toward the lung parenchyma. This allows angiotensin 2 to cause lung injury [39].

Furthermore, there is more potassium loss in the urine and increased aldosterone secretion by the virus [17]. Nevertheless, more studies need to be conducted to assess the full potential effects of ACE2 expression concerning diabetes and COVID-19. Predictions and decisions can be made if angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, TZDs, GLP-1 agonists, and statins reduce ACE2 appearance in COVID patients.

DM also causes impairment in the activation of the adaptive immune response by inhibiting stimulation of Th1 cell-mediated immunity, thereby leading to a delayed hyperinflammatory reaction in diabetic patients [40]. A study that examined DM effects in mouse models of MERS-Cov infectivity showed that the infection was further prolonged and severe in diabetic male mice. This was because of the variations in CD4+ T cell counts and aberrant cytokine responses [41]. This finding is fairly consistent with SARS-CoV-2 patients, with peripheral counts of CD4+ and CD8T cell counts being abnormally low but subsequently having higher levels of proinflammatory Th17 cells and elevated cytokine count [42,43]. This demonstrated that DM patients have a severely blunted anti-viral response compared to a fairly accentuated inflammatory response because of delayed activation of Th1/Th17 [42]. The SARS-CoV-2 productively infects β-cell and can trigger acute insulin secretion impairment or β-cells loss, which can initiate diabetes [44].

To understand the possible causal association between chronic untreated hyperglycemia and higher death rates in COVID-19 patients, certain biological pathways have been suggested. The primary cause of mortality in COVID-19 patients with diabetes is an inadequate immune response to viral infections [45]. The increased blood sugar level is expected to substantially affect the intracellular degradation of bacteria, neutrophil chemotaxis, and phagocytosis, thus improving viral binding affinity and entry and decreasing virus clearance [46]. In addition, it has significant effects on the proteins by inducing glycosylation and altering the composition of complements [47,48], and glycosylation renders cells susceptible to viral inflammation and damage [49,50]. In addition, endotheliitis may be a potential pathway that triggers organ dysfunction that causes essential COVID-19 disease, aggravated by endothelial dysfunction coupled with chronic hyperglycemia [51].

Multiple variables are associating diabetes with infection severity. The acute inflammatory response can be triggered, intensified, or prolonged by hyperglycemia [52]. It also induces a coagulation and fibrinolysis mismatch, resulting in elevated coagulation factors and relative fibrinolytic system inhibition, fostering a pro-coagulant state [53]. Moreover, SARS-CoV-2 is suspected to be using the ACE2 as the entry receptors on the Langerhans islets. This can lead to moderate to dawning of these cells, leading to moderate hyperglycemia to life-endangering diabetic ketoacidosis [50].

Diabetic people’s vulnerability during a public health epidemic turns out to be evident in the COVID-19 pandemic because of their at least twice higher risk of severe illness or death, particularly in people with poorly regulated diabetes and comorbidities, or both. The pressure on healthcare organizations and the world economy because of COVID-19, compounded by chronic diseases like diabetes, has been enormous [21] (Table 1).

An extensive survey showed that respondents had a low knowledge score regarding COVID-19. In this respect, it becomes more important to be aware of COVID-19 and its consequences on human health [54]. Establishing a valid association between DM and COVID-19 is imperative in treating DM patients. It would also help in DM care in the present conditions and assist in similar outbreaks in the future. It is also essential to take care of the comorbidities of DM patients while treating DM. Now that the COVID-19 vaccine is available, we need to get vaccinated to save ourselves from this highly infectious disease and save other society members.
Table 1: Outcome risks among COVID-19 patients with diabetes

| Authors            | Article type | Study population | Prevalence of diabetes | Outcome                  | Risk            |
|--------------------|--------------|------------------|------------------------|--------------------------|-----------------|
| Parohan et al. [25]| Meta-analysis| 27,352           | —                      | Mortality                | 2.41 (1.05–5.51)|
| Zhu et al. [31]    | Meta-analysis| 1,180            | —                      | Mortality                | 2.3 (1.679–3.150)|
| Kumar et al. [55]  | Meta-analysis| 16,003           | 9.8%                   | Mortality                | 1.9 (1.372–2.64)|
| Wei et al. [56]    | Prospective  | 167              | 6.59%                  | Severity                 | 10.12 (2.742–37.347)|
| Simonnet et al. [57]| Prospective | 124              | 23%                    | Invasive mechanical      | 2.45 (0.67–3.49)|
| Wu et al. [58]     | Retrospective| 201              | 10.9                   | ARDS                     | 2.34 (1.35–4.05)|
| Wu et al. [58]     | Retrospective| 201              | 10.9%                  | Mortality                | 1.58 (0.80–3.13)|
| Mo et al. [59]     | Retrospective| 155              | 9.7%                   | Refractory COVID-19      | 2.138 (0.483–9.471)|
| Huang et al. [60]  | Meta-analysis| 6,452            | 26.48%                 | Mortality                | 2.12 (1.44–3.11)|
| Huang et al. [60]  | Meta-analysis| 6,452            | 26.48%                 | ARDS                     | 4.64 (1.86–11.58)|
| Huang et al. [60]  | Meta-analysis| 6,452            | 26.48%                 | Severe COVID-19          | 2.45 (1.79–3.35)|
| Tian et al. [61]   | Meta-analysis| 4,659            | 23.8%                  | Mortality                | 2.0 (1.7–2.3)  |

ARDS = acute respiratory distress syndrome.

The community must also implement social distancing guidelines and protocols to protect those who are more susceptible to morbidity from this disease, such as comorbid individuals or older aged people. Comorbid individuals are those who are more severely being infected by the virus. Patients with chronic illnesses like diabetes, hypertension, and respiratory diseases are more threatened by the virus than those without any underlying conditions.

The treatment of COVID-19 patients with diabetes requires an integrated team approach to minimize the risk of medical complications and mortality [44]. Besides, doctors should incorporate pragmatic measures to treat patients with comorbidities. This strategy would help reduce the frequency of complications, mortality among patients, and the healthcare system’s overall load.

4 Conclusion

COVID-19 is an ongoing pandemic with new information concerning the disease continually emerging. Diabetes is an essential comorbid factor for COVID-19, and diabetic patients must take the necessary steps to prevent them from becoming infected. More research is required to cater a clearer understanding of the prevalence of morbidity, mortality, and pathophysiology of COVID-19 in diabetic patients.

Funding: The author states no funding involved.

Conflict of interest: The author states no conflict of interest.

Data availability statement: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

[1] Ahmad T, Haroon, Baig M, Hui J. Coronavirus disease 2019 (COVID-19) pandemic and economic impact. Pak J Med Sci. 2020;36(COVID19-54):51–6.
[2] Huang YT, Lee YC, Hsiao CJ. Hospitalization for ambulatory-care-sensitive conditions in Taiwan following the SARS outbreak: a population-based interrupted time series study. J Formos Med Assoc. 2009;108:386–94.
[3] Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003 Nov;8:59–14.
[4] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92.
[5] Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502.
[6] Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel Coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–60.
[7] Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532:107–10.
[8] Li YC, Bai WZ, Hashikawa T. Response to commentary on the neuroinvasive potential of SARS-CoV-2 may play a role in the
respiratory failure of COVID-19 patients. J Med Virol. 2020;92:707–9.

[9] Palm NW, Medzhitov R. Not so fast: adaptive suppression of innate immunity. Nat Med. 2007;13:1142–4.

[10] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Across specialty collaboration. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033.

[11] Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020.

[12] Hafidh K, Abbas S, Khan A, Kazmi T, Nazir Z, Aldaham T. The clinical characteristics and outcomes of COVID-19 infections in patients with diabetes at a tertiary care center in the UAE. Dubai Diabetes Endocrinol J. 2021;26:1–6.

[13] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531–8.

[14] Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–22.

[15] Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care. 2020;43:1382–91.

[16] Holman N, Knighton P, Kar P, O’Keeffe J, Curley M, Weaver A, et al. Risk factors for COVID-19 related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823–33.

[17] Guan WJ, Ntiz Y, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.

[18] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020;323:1239–42.

[19] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.

[20] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. J Am Med Assoc. 2020;323:2052–9.

[21] Chan JC, Lim LT, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The lancet commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2020;396:2019–82.

[22] Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4:148–58.

[23] McDonald HI, Nitsch D, Millett ER, Sinclair A, Thomas SL. New estimates of the burden of acute community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using linked electronic health records. Diabetic Med. 2014;31:606–14.

[24] Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes mellitus and cause-specific mortality: a population-based study. Diabetes Metab J. 2019;43:319–41.

[25] Paroham M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;1–9. doi: 10.1080/13685538.2020.1774748.

[26] Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. J Am Med Assoc. 2020;323:1775–6.

[27] Yang JY, Feng Y, Yuan MY, Yuan SY, Fu H, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med. 2006;23:623–8.

[28] Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14:813–21.

[29] Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1068–77.

[30] Al Hayek AA, Robert AA, Matar AB, Algarani A, Alkubedan H, Alharbi T, et al. Risk factors for hospital admission among COVID-19 patients with diabetes. Saudi M J. 2020;41:1090–7.

[31] Zhu Z, Mao Y, Chen G. Predictive value of HbA1C for adverse prognosis in COVID-19: a systematic review and meta-analysis. SSRN. 2021. ID:ppcovidwho-6421.

[32] Sur J, Sharma J, Sharma D. Diabetes might augment the severity of COVID-19: a current prospects. Front Cardiovasc Med. 2020;7:61255.

[33] Roca-Ho H, Riera M, Palau V, Pascual J, Soler MI. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci. 2017;18:563.

[34] Wysocki J, Ye M, Soler MI, Curley SB, Xiao HD, Bernstein KE, et al. ACE and ACE2 activity in diabetic mice. Diabetes. 2006;55:2132–9.

[35] Rao S, Lau A, So HC. Exploring diseases/trails and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a Mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care. 2020;43:1416–26.

[36] Fernandez C, Rysaj A, Almgren P, Nilsson J, Engström G, Orholmelander M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Inter Med. 2018;284:377–87.

[37] Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. MedRxiv. 2020. doi: 10.1101/2020.03.22.20040774.

[38] Wösten-van Asperen RM, Bos AP, Bem RA, Dierdorf BS, Dekker T, et al. Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. Pediatr Crit Care Med. 2013;14:e438–41.

[39] Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus – induced lung injury. Nat Med. 2005;11:875–9.

[40] Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden
of diabetes and intracellular bacterial infections. Immunology. 2015;144:171–85.

[41] Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4:e131774.

[42] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.

[43] Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. Respir Med. 2020;8:475–81.

[44] Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–92.

[45] Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, et al. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41:2127–35.

[46] Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318:E736–41.

[47] Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 2016;351:201–11.

[48] Wang Q, Fang P, He R, Li M, Yu H, Zhou L, et al. D-GlcNAc transferase promotes influenza A virus–induced cytokine storm by targeting interferon regulatory factor–5. Sci Adv. 2020;6:eeaz7086. doi: 10.1126/sciadv.aaaz7086.

[49] Bornstein SR, Rubinov F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546–50.

[50] Yang JK, Lin SS, Ji XJ, Guo LM, Ji X, Ji X, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193–9.

[51] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.

[52] Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabet Med. 1992;18:187–201.

[53] Schuetz P, Castro P, Shapiro N. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care. 2011;34:771–89.

[54] Tariq S, Tariq S, Baig M, Saeed M. Knowledge, awareness and practices regarding novel coronavirus among a sample of Pakistani population, a cross-sectional study. Disaster Med Public Health Prep. 2020;1–20. doi: 10.1017/dmp.2020.408.

[55] Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;14:535–45.

[56] Wei Y-Y, Wang R-R, Zhang D-W, Tu Y-H, Chen C-S, Ji S, et al. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020;81:e89–92.

[57] Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;28:1195–9.

[58] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China JAMA Intern Med. 2020;180:934–43.

[59] Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa270.

[60] Huang J, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14:395–403.

[61] Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2020;92:1875–83.